MARKET

EIGR

EIGR

Eiger Biopharma
NASDAQ
7.00
+1.40
+25.00%
After Hours: 6.87 -0.13 -1.86% 19:51 03/01 EST
OPEN
5.90
PREV CLOSE
5.60
HIGH
8.01
LOW
5.90
VOLUME
39.40K
TURNOVER
0
52 WEEK HIGH
57.90
52 WEEK LOW
5.12
MARKET CAP
10.36M
P/E (TTM)
-3.5711
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at EIGR last week (0219-0223)?
Weekly Report · 6d ago
Weekly Report: what happened at EIGR last week (0212-0216)?
Weekly Report · 02/19 11:02
Weekly Report: what happened at EIGR last week (0205-0209)?
Weekly Report · 02/12 10:53
Weekly Report: what happened at EIGR last week (0129-0202)?
Weekly Report · 02/05 11:00
Weekly Report: what happened at EIGR last week (0122-0126)?
Weekly Report · 01/29 10:51
Eiger BioPharmaceuticals CCO Eldon Mayer III Resigns
TipRanks · 01/25 09:47
Eiger Biopharma: Current report
Press release · 01/24 22:29
Weekly Report: what happened at EIGR last week (0115-0119)?
Weekly Report · 01/22 10:54
More
About EIGR
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.

Webull offers Eiger Biopharmaceuticals Inc stock information, including NASDAQ: EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EIGR stock methods without spending real money on the virtual paper trading platform.